DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Bidil (Hydralazine Hydrochloride / Isosorbide Dinitrate) - Summary

 


Nutrilib.com
A comprihensive source of nutritional information

BIDIL SUMMARY

BiDil ®  
(isosorbide dinitrate and hydralazine hydrochloride)
Tablets

BiDil is a fixed-dose combination of isosorbide dinitrate, a vasodilator with effects on both arteries and veins, and hydralazine hydrochloride, a predominantly arterial vasodilator.

BiDil is indicated for the treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to prolong time to hospitalization for heart failure, and to improve patient-reported functional status. There is little experience in patients with NYHA class IV heart failure. Most patients in the clinical trial supporting effectiveness (A-HeFT) received a loop diuretic, an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker, and a beta blocker, and many also received a cardiac glycoside or an aldosterone antagonist.


See all Bidil indications & dosage >>

BIDIL NEWS HIGHLIGHTS

Media Articles Related to Bidil (Hydralazine Hydrochloride / Isosorbide Dinitrate)

New Theory That May Lead To Effective Heart Failure Treatments
Source: Transplants / Organ Donations News From Medical News Today [2008.11.13]

AHA: Exercise Significantly Improves Quality of Life Measures in Heart Failure Patients
Source: MedPage Today Cardiovascular [2008.11.13]

Heart Failure Accounts for 37% of Medicare Spending
Source: MedicineNet Chronic Obstructive Pulmonary Disease (COPD) Specialty [2008.11.13]

AHA: Biomarker Beats BNP for Heart Failure Mortality Prediction
Source: MedPage Today Emergency Medicine [2008.11.12]

Heart Failure Accounts for 37% of Medicare Spending (HealthDay)
Source: Y! Health Heart & Vascular Health News [2008.11.12]

more >>

Published Studies Related to Bidil (Hydralazine Hydrochloride / Isosorbide Dinitrate)

Evidence for the continued safety and tolerability of fixed-dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African-American Heart Failure Trial). [2007.08.15]

Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. [2007.06]

Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. [2007.04.03]

A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination. [2006.05]

Flaws in the U.S. Food and Drug Administration's rationale for supporting the development and approval of BiDil as a treatment for heart failure only in black patients. [2008.09]

more >>

Clinical Trials Related to Bidil (Hydralazine Hydrochloride / Isosorbide Dinitrate)

African-American Heart Failure Trial [Completed]

more >>

Page last updated: 2008-11-13

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008